Study of Sargramostim in Moderately to Severely Active Crohn's Disease

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2006
The purpose of this study is to assess the tolerability, pharmacokinetics and safety of 2 and 6 micro g/kg/day sargramostim administered subcutaneously once daily for 4 weeks, and to assess the efficacy and safety of 6 micro g/kg/day sargramostim administered subcutaneously once daily for 8 weeks in comparison with placebo, in patients with moderately to severely active Crohn\'s disease.
Epistemonikos ID: 438a18da8326f40d3977a3e14b12aa7a59821b02
First added on: May 04, 2024